NasdaqCM - Delayed Quote USD

Surrozen, Inc. (SRZNW)

Compare
0.0325 +0.0076 (+30.52%)
At close: January 2 at 4:00:00 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for SRZNW

Recent News: SRZNW

View More

Surrozen to Present at Upcoming Healthcare Investor Conferences
GlobeNewswire last month

Surrozen Provides Third Quarter 2024 Financial Results and Business Update
GlobeNewswire last month

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
GlobeNewswire last month
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
GlobeNewswire 3 months ago
Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky

Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky
Simply Wall St. 4 months ago
Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Surrozen Provides Second Quarter 2024 Financial Results and Business Update
GlobeNewswire 4 months ago
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
GlobeNewswire 6 months ago
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
GlobeNewswire 6 months ago
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
GlobeNewswire 6 months ago
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
GlobeNewswire 7 months ago
Surrozen Provides First Quarter 2024 Financial Results and Business Update

Surrozen Provides First Quarter 2024 Financial Results and Business Update
GlobeNewswire 7 months ago
View More